Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple claims re-characterize label-supported dizziness/somnolence as 'muscle weakness' and extrapolate to coordination, balancing, and walking instability without support in the provided label sections. Kidney-related exposure/dosing adjustment and abrupt discontinuation guidance are supported, but overall label adherence fails due to repeated unsupported reframing.
Category Scores
Accurate Statements
Pregabalin exposure depends partly on kidney function.
8 2.7 (dose adjust for reduced renal function; primarily renal excretion) and 12.3 (eliminated largely by renal excretion).
Clinicians may adjust pregabalin dosing based on kidney function to reduce the risk of excessive side effects like weakness or marked sedation.
8 2.7 (adjust dose in adult patients with reduced renal function due to dose-dependent adverse reactions) and 5.5 (somnolence).
Patients should not stop Lyrica (pregabalin) abruptly without medical guidance.
5.6 (withdraw/taper gradually; do not discontinue abruptly).
Unsupported Statements
Lyrica (pregabalin) can affect nervous system signaling in a way that sometimes leads to muscle weakness.
The provided label excerpts discuss CNS dizziness and somnolence (5.5) and MOA binding (12.1) but do not explicitly describe 'muscle weakness' as a labeled adverse effect in the supplied sections.
Pregabalin may cause reduced muscle strength or heaviness in the limbs.
No labeled mention of reduced muscle strength or limb heaviness in the provided sections.
Pregabalin may cause trouble with coordination.
No labeled statement of coordination trouble in the provided sections (5.5 addresses dizziness/somnolence).
Pregabalin may cause difficulty performing normal activities due to weakness.
5.5 supports impairment of tasks such as driving due to dizziness/somnolence, not difficulty due to 'weakness.'
Dizziness or trouble balancing can be described as weakness and can make walking or standing feel unstable with pregabalin.
5.5 supports dizziness/somnolence may impair tasks, but does not equate these to 'weakness' or state walking/standing instability.
Sleepiness or fatigue can be described as weakness and can reduce perceived strength with pregabalin.
5.5 supports somnolence/sleepiness, but does not characterize them as 'weakness' or 'reduced perceived strength.'
Slowed coordination or impaired motor control can be mistaken for purely muscle problems with pregabalin.
No labeled statements about slowed coordination, impaired motor control, or diagnostic misattribution in the provided sections.
The effects described as weakness can be tied to pregabalin’s action on brain and nerve excitability.
12.1 provides MOA binding/mechanistic discussion, but the provided excerpts do not specifically link 'weakness' (as claimed) to nerve excitability.
Higher pregabalin exposure can increase the likelihood of side effects that affect coordination, alertness, and overall muscle control.
5.5 supports increased frequency of dizziness/somnolence at higher doses and 8 2.7 supports dose-dependent adverse reactions; however, the provided excerpts do not mention coordination, alertness, or overall muscle control as side-effect domains.
Clinicians may adjust pregabalin dosing based on kidney function to reduce the risk of excessive side effects like weakness or marked sedation.
Dose adjustment for reduced renal function and somnolence is supported, but 'weakness' is not explicitly supported in the provided label excerpts as a dose-dependent adverse reaction.
Muscle weakness can occur if pregabalin is stopped suddenly.
5.6 describes increased seizure frequency risk and discontinuation symptoms (insomnia, nausea, etc.) but does not list muscle weakness.
Muscle weakness can occur if other medications that affect the nervous system are taken together with pregabalin.
7 in the provided excerpts states pharmacokinetics are unlikely to be affected and lists no pharmacokinetic interactions with specific antiepileptics; it does not support muscle-weakness interactions due to co-medications.
Sedatives or other drugs that cause drowsiness or impair coordination are examples of medications that can be involved in weakness with pregabalin.
The provided excerpts support dizziness/somnolence as LYRICA effects, but do not identify sedatives/coordination-impairing drugs as causing or contributing to 'weakness.'
Contradictions
Low
AI Statement
None of the unsupported 'muscle weakness' re-framings directly contradict the provided label text.
Label Reference
N/A
Important Omissions
No label-supported clarification that the provided sections specifically describe dizziness and somnolence (and their impairment of tasks) rather than muscle weakness, coordination trouble, balancing instability, or reduced muscle strength.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Primary issue is mislabeling/extrapolation of CNS effects (dizziness/somnolence) as 'muscle weakness' and linking additional symptom clusters (coordination, walking/standing instability) without label support, which could misinform clinical interpretation. Label-supported warnings about dizziness/somnolence and tapering are partially captured.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Repeated unsupported reframing of dizziness/somnolence as 'muscle weakness' plus extrapolated coordination/balance/walking instability and muscle control claims not supported by the provided label excerpts.
Suggested Improvement
Restrict symptom descriptions to the label-supported terms (e.g., dizziness and somnolence) and avoid equating them to 'weakness' or adding coordination/balance/motor-control impairment unless explicitly supported in the supplied label sections. For discontinuation, keep the label-supported tapering guidance. For renal function, keep the label-supported dose adjustment concept.